ArticleJCI insight2022

Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC.

Eric Tu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.